Genespire

Genespire is a private, preclinical-stage biotech developing advanced gene therapies using its proprietary immune-shielded lentiviral vector platform. Founded in 2019 and based in Milan, Italy, the company aims to address a key limitation in gene therapy—immune system rejection of the viral vector—to create more effective and durable treatments for severe genetic diseases, particularly in pediatric populations. The leadership team combines deep expertise in gene therapy development, CMC, and venture capital from Sofinnova Partners, which is a key investor. The company is currently in the platform and early asset development phase, positioning itself in the competitive but high-potential field of gene therapy.

Immune-shielded lentiviral vectors designed to evade host immune system recognition and rejection, enabling more effective and potentially re-dosable ex vivo gene therapies.

Genespire competes in the advanced gene therapy vector space. Direct competitors include companies engineering AAV capsids for immune evasion (e.g., Dyno Therapeutics, Affinia) and other lentiviral vector innovators. It also competes broadly with all gene therapy developers targeting rare monogenic diseases. Its differentiation hinges on the success of its specific lentiviral shielding approach.